{"id":1016520,"date":"2026-11-02T21:18:21","date_gmt":"2026-11-03T02:18:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"modified":"2026-11-02T21:18:21","modified_gmt":"2026-11-03T02:18:21","slug":"nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","title":{"rendered":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Fort Lee, NJ, Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.\u00a0<\/p>\n<p>\n        <b>Conference Call and Webcast Information: <\/b><br \/>\n        <br \/>Date: 8:00 AM ET, Wednesday, November 4, 2026<br \/>Participant Dial-In (U.S.): 1-877-407-0752<br \/>Participant Dial-In (International): 1-201-389-0912<br \/>Conference ID: 13763643<br \/>Webcast Access: Please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oLY_ByEMgM6oWGVJ_Ei9IjDlDWYwpHpZaPYaxybjWd54lXjov5pcke-iMqbL9KPG6ABuOanXgQ9VgJYWQramzyAzjVGCpITZhEEAwbM0_S0EuZPaHQlSAPMU92JUCsH6Mosxz2uvGz6P2eY2snkTaQ==\" rel=\"nofollow\" target=\"_blank\">here<\/a><\/p>\n<p>The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.<\/p>\n<p>\n        <b>About Nuvectis Pharma, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company\u2019s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.<\/p>\n<p align=\"justify\">The company\u2019s lead drug candidate is NXP100 (ciprocopan), a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.<\/p>\n<p align=\"justify\">NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II\/III non-V600-mutated solid tumor malignancies, with best-in-class potential.<\/p>\n<p align=\"justify\">NXP900 is an oral, small molecule inhibitor of the SRC family kinases, including SRC and YES1.<\/p>\n<p align=\"justify\">\n        <b>Company Contact:<\/b>\n      <\/p>\n<p align=\"justify\">Ron Bentsur<br \/>Chairman, Chief Executive Officer and President <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AoYcsvp4HIBbrgxctLYs4UODZJLPqxwZBJUkdmw4B2StvEyQTJIX8c0yP5TLRRvLm2zZciQii-h5AhmmSBaB-g3VKanA1nO2qnncX40qQyI=\" rel=\"nofollow\" target=\"_blank\">rbentsur@nuvectis.com<\/a><\/p>\n<p align=\"justify\">\n        <b>Media Relations Contact:<\/b>\n      <\/p>\n<p align=\"justify\">Kevin Gardner<br \/>LifeSci Advisors<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lvk0cgN60o5lsMfEn_lInMyG4ZwwtUYAfRK25YSs1fMn3268MwaltDWOT4TxCYeMdfbVQcy1S5N8qK6fTy7M1zPrviIdJH-9-kL-KokN9JO5o85df6t__lx5poPOtFhh\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQ3ZWYwMDUtMTVjNS00NDNkLTkwYWMtMTdlYTAwMTE0OWQ3LTUwMDA4MjgxNy0yMDI2LTExLTAyLWVu\/tiny\/Nuvectis-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.\u00a0 Conference Call and Webcast Information: Date: 8:00 AM ET, Wednesday, November 4, 2026Participant Dial-In (U.S.): 1-877-407-0752Participant Dial-In (International): 1-201-389-0912Conference ID: 13763643Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016520","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.\u00a0 Conference Call and Webcast Information: Date: 8:00 AM ET, Wednesday, November 4, 2026Participant Dial-In (U.S.): 1-877-407-0752Participant Dial-In (International): 1-201-389-0912Conference ID: 13763643Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of &hellip; Continue reading &quot;Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T02:18:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026\",\"datePublished\":\"2026-11-03T02:18:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"},\"wordCount\":307,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\",\"name\":\"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\",\"datePublished\":\"2026-11-03T02:18:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","og_description":"Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.\u00a0 Conference Call and Webcast Information: Date: 8:00 AM ET, Wednesday, November 4, 2026Participant Dial-In (U.S.): 1-877-407-0752Participant Dial-In (International): 1-201-389-0912Conference ID: 13763643Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of &hellip; Continue reading \"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-03T02:18:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026","datePublished":"2026-11-03T02:18:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"},"wordCount":307,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/","name":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==","datePublished":"2026-11-03T02:18:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODEwNyM3OTQwMDUxIzUwMDA4MjgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016520"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016520\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}